Their study demonstrated the basis of the potential benefits of GLP-1R agonism in neurons and astrocytes, and it pinpoints who is most likely to gain from GLP-1R agonism and underscores the effectiveness of GLP-1R agonism as a strategy to modify diseases in synucleinopathies. This evidence concerns the gene GLP1R and synucleinopathy.